ArticleFrontiers in public health2026
Epidemiology of drug-resistant tuberculosis in Hunan China over a 10-year period.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major public health challenge in China, yet long-term epidemiological data from key regions such as Hunan Province in South-Central China are still limited. Objective: This study aimed to characterize the epidemiological trends, spatial distribution, and risk factors of Single drug-resistant tuberculosis (SDR-TB), poly-drug-resistant tuberculosis (PDR-TB), multidrug-resistant tuberculosis (MDR-TB), rifampicin-resistant tuberculosis (RR-TB), and isoniazid-resistant tuberculosis (INH-R TB) in Hunan Province between 2014 and 2023, to inform region-specific control strategies. Methods: It was a retrospective analysis that was conducted on 6,597 laboratory-confirmed DR-TB cases. Data were obtained from the Provincial Tuberculosis Control Institute. All patients underwent phenotypic drug susceptibility testing. Independent risk factors for DR-TB subtypes were identified through multivariable logistic regression, with adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) calculated. Results: A total of 6,597 patients with DR-TB were included in this 10-year analysis. Among them, 74.97% were male and 64.44% were farmers. The highest case burden was observed in the 50-59 age group (24.78%). Spatially, cases clustered mainly in the Changsha (16.39%), Shaoyang (13.78%), and Loudi (9.05%). The most common resistance subtypes were INH-R TB (56.27%) and MDR-TB (52.37%). The distribution of all DR-TB subtypes varied significantly across age groups ( Conclusion: This study presents a 10-year epidemiological assessment of DR-TB in Hunan Province, China, covering 2014-2023. A disproportionately high burden was observed among middle-aged and older male farmers. The predominance of INH-R TB and MDR-TB, together with distinct regional and demographic risk profiles, underscores an urgent need to strengthen TB control measures. These results support the implementation of targeted interventions, including intensified screening in high-risk populations and in high-incidence areas, along with optimized treatment regimens, to curb the ongoing DR-TB epidemic in South-Central China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.